HighTower Advisors
PCRX icon

HighTower Advisors’s Pacira BioSciences PCRX Stock Holding History

HighTower Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$617K Sell
24,318
-6,188
-20% -$146K ﹤0.01% 2574
2026
Q1 		$689K Buy
30,506
+6,534
+27% +$145K ﹤0.01% 2456
2025
Q4 		$620K Buy
23,972
+10,802
+82% +$257K ﹤0.01% 2458
2025
Q3 		$339K Buy
+13,170
New +$323K ﹤0.01% 2937
2024
Q3 		– Sell
-14,621
Closed -$421K – 3908
2024
Q2 		$421K Buy
14,621
+110
+0.8% +$3.13K ﹤0.01% 2439
2024
Q1 		$424K Buy
14,511
+5,715
+65% +$176K ﹤0.01% 2389
2023
Q4 		$296K Buy
8,796
+865
+11% +$25.3K ﹤0.01% 2710
2023
Q3 		$242K Buy
+7,931
New +$286K ﹤0.01% 2764
2022
Q2 		– Sell
-34,201
Closed -$2.6M – 3464
2022
Q1 		$2.6M Buy
34,201
+30,812
+909% +$2.05M 0.01% 1225
2021
Q4 		$203K Sell
3,389
-157
-4% -$8.66K ﹤0.01% 2767
2021
Q3 		$200K Buy
3,546
+163
+5% +$9.39K ﹤0.01% 2715
2021
Q2 		$203K Buy
3,383
+9
+0.3% +$570 ﹤0.01% 2659
2021
Q1 		$238K Hold
3,374
– – ﹤0.01% 2466
2020
Q4 		$200K Sell
3,374
-1,000
-23% -$58.6K ﹤0.01% 2205
2020
Q3 		$260K Buy
4,374
+474
+12% +$27.5K ﹤0.01% 1915
2020
Q2 		$205K Buy
+3,900
New +$163K ﹤0.01% 1984
2019
Q1 		– Sell
-5,535
Closed -$237K – 2392
2018
Q4 		$237K Sell
5,535
-68
-1% -$3.17K ﹤0.01% 1732
2018
Q3 		$274K Buy
+5,603
New +$242K ﹤0.01% 1770
2018
Q1 		– Sell
-6,000
Closed -$275K – 2296
2017
Q4 		$275K Hold
6,000
– – ﹤0.01% 1746
2017
Q3 		$226K Buy
+6,000
New +$241K ﹤0.01% 1832
2016
Q2 		– Sell
-4,147
Closed -$219K – 1952
2016
Q1 		$219K Sell
4,147
-78
-2% -$4.56K ﹤0.01% 1769
2015
Q4 		$325K Buy
+4,225
New +$239K ﹤0.01% 1526

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

HighTower Advisors's PCRX Position: Q2 2026 in Review

HighTower Advisors reduced its Pacira BioSciences (PCRX) stake by 20% in Q2 2026, selling an estimated $146K and leaving 24,318 shares worth $617K. The position accounts for ﹤0.01% of the portfolio, ranked #2574.

HighTower Advisors first reported a position in PCRX in Q4 2015 and has held it in 22 quarters since. The position peaked at $2.6M in Q1 2022. 97 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • HighTower Advisors held 24,318 shares of Pacira BioSciences worth $617K as of Q2 2026.
  • HighTower Advisors sold 6,188 Pacira BioSciences shares in Q2 2026, an estimated $146K.
  • Pacira BioSciences made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2574 holding.
  • HighTower Advisors first reported a position in Pacira BioSciences in Q4 2015 and has held it in 22 quarters since.
  • HighTower Advisors's Pacira BioSciences position peaked at $2.6M in Q1 2022.
  • 97 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.